Skip to main content

Envisioning is a research institute that studies how institutions adapt to technological change.

LinkedIn Instagram GitHub

Since 2010

Observatory
Adaptive capacity
Hindsight
Newsletter
Methodology
Origins
Vocab
RSS feeds

Signals Session
Bespoke Projects
Build Sessions
Pricing
Use cases
Signals
Signal Scanfree

ANBIMAFuture of Brazilian Capital Markets
IEEECharting the Energy Transition
Horizon 2045Future of Human and Planetary Security
WKOTechnology Scanning for Austria

solutions

Innovation
Strategy
Consultants
Foresight
Associations
Governments
L&D

resources

Partners
Coding for Non-Coders
Git for non-coders
How we work
Data visualization
Multi-Model Convergence
FAQ
Security and privacy
Public sector

Manifesto
Community
Events
Support
Contact

Research Capability Services Signals About

Research Capability Services Signals About

Dual-Action Antibodies · Hindsight | Envisioning

Hindsight · review build · data not yet validated

Dual-Action Antibodies

MIT Technology Review, 10 Breakthrough Technologies, 2010, published 2010-04-20

Publishers Envisioning Hype Cycle explorer Forecast vs actual

Fighting cancer more efficiently.

Source

Verdict

Not graded yet.

All captured fields

rank: 9
key players: ["Genentech","Roche","Scripps Research Institute","CovX","Pfizer"]
confidence: medium

Permalink

https://www.envisioning.com/hindsight/claims/mit-tr-10-breakthrough-2010-009

Cite

Hindsight, claim mit-tr-10-breakthrough-2010-009. Envisioning. https://www.envisioning.com/hindsight/claims/mit-tr-10-breakthrough-2010-009

Dispute this verdict

Data, code and grading rules are public at github.com/envisioning/hindsight. Data under CC BY 4.0 (the BCB Focus survey under ODbL), code under MIT. Every rule is in the decision log. Think a verdict is wrong? Open a dispute.